Study aims to predict IBD patient response to treatment
Personalised medicine is a term that has seen a major increase in interest and popularity recently, but I am here to tell you, the potential benefits for IBD patients could be a major game changer!
Cure Crohn’s Colitis have invested £60,000 into a project which has the potential to predict an IBD patients response to treatment.
Tariq Ahmad, head of The Exeter IBD and Pharmacogenetics Research group said “Our research focuses on the development of genetic tests to enable clinicians to select the most appropriate therapies for individual IBD patients, maximizing benefit and minimising harm from adverse drug reactions. Our goal is to use genetic technologies to advance prescribing from the current trial and error approach to allow the selection of the right drug, at the right dose, for the right patient, first time. We have employed the latest genome sequencing techniques to identify predictive genetic markers of drug response and side effects.”
Read more on the #IBDSuperHeroes blog.
